Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders: 2014-2025

Historic Net Income towards Common Stockholders for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to -$544,000.

  • Zevra Therapeutics' Net Income towards Common Stockholders rose 98.36% to -$544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 139.40%. This contributed to the annual value of -$105.5 million for FY2024, which is 129.13% down from last year.
  • Per Zevra Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$544,000 for Q3 2025, which was down 100.73% from $74.7 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Net Income towards Common Stockholders high stood at $74.7 million for Q2 2025, and its period low was -$47.7 million during Q1 2021.
  • Over the past 3 years, Zevra Therapeutics' median Net Income towards Common Stockholders value was -$11.8 million (recorded in 2023), while the average stood at -$7.2 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Net Income towards Common Stockholders slumped by 1,345.05% in 2021, and later soared by 474.94% in 2025.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Net Income towards Common Stockholders stood at -$2.7 million in 2021, then plummeted by 233.74% to -$9.0 million in 2022, then slumped by 120.51% to -$19.9 million in 2023, then slumped by 79.67% to -$35.7 million in 2024, then skyrocketed by 98.36% to -$544,000 in 2025.
  • Its Net Income towards Common Stockholders was -$544,000 in Q3 2025, compared to $74.7 million in Q2 2025 and -$3.1 million in Q1 2025.